News - BioHarvest Sciences

News Room

February 18, 2025

BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD

February 12, 2025

BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar

February 11, 2025

BioHarvest Sciences Announces Voluntary Delisting from CSE

January 22, 2025

BioHarvest Announces Appointment of Sharon Malka to Board of Directors

January 8, 2025

BioHarvest Issues Shareholder Letter and Provides Corporate Update

December 11, 2024

Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of  Ingredients through Botanical Synthesis Technology

November 25, 2024

BioHarvest Sciences Reports Third Quarter 2024 Financial Results

November 25, 2024

BioHarvest Launches VINIA SuperFood Functional Tea Line

November 21, 2024

BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024

November 18, 2024

BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 p.m. Eastern Time

November 12, 2024

BioHarvest Sciences Begins Trading on the Nasdaq Global Market

December 27, 2023

BIOHARVEST SCIENCES INC. CLOSES FINAL TRANCHE OF OVERSUBSCRIBED $13.5M PRIVATE PLACEMENT

December 13, 2023

BIOHARVEST SCIENCES ANNOUNCES MAJOR PRODUCT LAUNCH OF VINIA-BASED FUNCTIONAL COFFEES

December 1, 2023

BIOHARVEST SCIENCES TO HOST VIRTUAL SHAREHOLDER UPDATE DECEMBER 13, 2023, 2:30pm ET

November 29, 2023

BIOHARVEST SCIENCES REPORTS Q3 2023 REVENUE DEMONSTRATING CONTINUED GROWTH MOMENTUM

October 30, 2023

BIOHARVEST SCIENCES INC. ANNOUNCES $11.78M RAISED IN FIRST TRANCHE OF $13.5M PRIVATE PLACEMENT

October 10, 2023

HEALTH CANADA GRANTS BIOHARVEST SCIENCES LICENSE FOR VINIA SALES IN CANADA

December 29, 2022

BIOHARVEST SCIENCES INC. 2022 CEO LETTER TO SHAREHOLDER PARTNERS

December 15, 2022

BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE THIRD TRANCHE OF CONVERTIBLE NOTES

December 15, 2022

BIOHARVEST SCIENCES INC. PROJECTS 2023 REVENUE TO GROW 3.0X-3.5X TO A RANGE OF USD $17M-$20M

November 16, 2022

ROYAL EMERALD PHARMACEUTICALS PARTNERS WITH BIOHARVEST SCIENCES TO SUPPLY DISRUPTIVE CANNABIS SOLUTIONS TO COMPANIES CONDUCTING FDA-APPROVED MEDICAL RESEARCH

November 15, 2022

BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND EXPECTS THE OFFERING TO BE OVERSUBSCRIBED AND TO CLOSE AN ADDITIONAL TRANCHE OF UP TO $3 MILLION BY DECEMBER 15, 2022

October 25, 2022

BIOHARVEST INTRODUCES ITS 1ST CANNABIS BREAKTHROUGH COMPOSITION WITH MAJOR MEDICAL AND COMMERCIAL IMPLICATIONS

December 30, 2021

BIOHARVEST SCIENCES INC. 2021 CEO LETTER TO SHAREHOLDER PARTNERS

December 12, 2021

UNPRECEDENTED BIOHARVEST MEDIA COVERAGE! Plus a request from CEO Ilan Sobel

December 8, 2021

BIOHARVEST SCIENCES INC. PRODUCES SIGNIFICANT AMOUNT OF CANNABIS WITHOUT GROWING THE CANNABIS PLANT

December 1, 2021

BIOHARVEST SCIENCES APPOINTS ASTRONAUT CHRIS HADFIELD TO THE BOARD OF ADVISORS

November 30, 2021

BHSC NOVEMBER NEWSLETTER

November 29, 2021

BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF STOCK OPTIONS

April 21, 2020

BioHarvest Sciences Inc. (formerly, Canna-V-Cell Sciences Inc. CSE Symbol: CNVC) Closes Agreement and Plan of Merger and announces the Results of its Annual General Meeting and Special Meeting

June 3, 2020

Bioharvest Sciences Inc. Announces Private Placement

June 9, 2020

BioHarvest Sciences Inc. Appoints Ilan Sobel as New CEO

June 10, 2020

BioHarvest Sciences Inc. Appoints Eitan Popper as Chairman of the Advisory Board